New trial tests if switching PARP inhibitors can help control advanced cancers
NCT ID NCT04550494
Summary
This study is testing whether the drug talazoparib can help control advanced cancers in patients whose tumors have specific mutations in genes that help repair DNA damage. It is enrolling 36 adults with various advanced solid tumors (like breast, ovarian, prostate, pancreatic, and gastric cancers) who have these mutations and whose disease has progressed after standard treatments. A key goal is to learn if patients who have already tried a different drug from the same class (a PARP inhibitor) might still benefit from trying talazoparib.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Institute Developmental Therapeutics Clinic
RECRUITINGBethesda, Maryland, 20892, United States
Contact
Contact Phone: •••-•••-••••
-
National Institutes of Health Clinical Center
ACTIVE_NOT_RECRUITINGBethesda, Maryland, 20892, United States
-
UF Health Cancer Institute - Gainesville
RECRUITINGGainesville, Florida, 32610, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.